Abstract

Interleukin-1 receptor antagonist (IL-1Ra) is a natural IL-1 inhibitor possessing anti-inflammatory properties. IL-1Ra is produced as different isoforms, one secreted (sIL-1Ra) and three intracellular (icIL-1Ra1, icIL-1Ra2 and icIL-1Ra3), derived from the same gene. We examined the production of IL-1Ra species by cultured human articular chondrocytes in response to various cytokines. The levels of IL-1Ra were undetectable in culture supernatants of untreated cells, but were significantly increased by IL-1beta. Cell lysates contained very low levels of IL-1Ra, even in response to IL-1beta, suggesting that chondrocytes produce predominantly sIL-1Ra. IL-6, which had no effect on its own, enhanced the effect of IL-1beta, while dexamethasone prevented the response. We observed by RT-PCR that IL-1beta and IL-6 induced primarily the production of sIL-1Ra mRNA. Furthermore, IL-1beta alone or combined with IL-6 increased the levels of nascent unspliced sIL-1Ra mRNA, suggesting that sIL-1Ra expression is regulated at the transcriptional level. Reporter gene assays in immortalized chondrocytes, C-20/A4, consistently showed increased sIL-1Ra promoter activity in response to IL-1beta and IL-6. In conclusion, human articular chondrocytes produce sIL-1Ra in response to IL-1beta and IL-6. The production of sIL-1Ra by chondrocytes may have a protective effect against articular inflammatory and catabolic responses.

Highlights

  • Interleukin-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family that binds to IL-1 receptors but does not induce any intracellular response

  • IL-1Ra production in articular chondrocytes IL-1Ra production was assessed in culture supernatants and lysates of chondrocytes incubated with various cytokines

  • IL-6 was used in combination with its soluble receptor, which is present in a high amount in the synovial fluid

Read more

Summary

Introduction

Interleukin-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family that binds to IL-1 receptors but does not induce any intracellular response. Therapeutic administration of IL-1Ra has beneficial effects in patients with rheumatoid arthritis [5]. Bp = base pairs; C/EBP = CCAAT/enhancer binding protein; DMEM = Dubecco’s modified Eagle’s medium; ELISA = enzyme-linked immunosorbent assay; F12 = NUT.MIX.F-12 (HAM) Media; FCS = fetal calf serum; icIL-1Ra = intracellular IL-1 receptor antagonist isoform; IL = interleukin; IL-1Ra = IL-1 receptor antagonist; NF = nuclear factor; PCR = polymerase chain reaction; RT = reverse transcription; sIL-1Ra = secreted IL-1 receptor antagonist isoform; sIL-6R = soluble IL-6 receptor; SEM = standard error of the mean. The sIL-1Ra and icIL-1Ra1 mRNAs are transcribed from different promoters and contain isoformspecific 5′ sequences due to alternative splicing [7,8]. The mRNA for icIL-1Ra2 is transcribed from the icIL-1Ra1 promoter, but contains an additional exon [9]. IcIL-1Ra3 is produced by alternative translation initiation from the sIL-1Ra transcript [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call